Do CD9, CD63 and CD81 alone prove exosome identity?

Tetraspanins such as CD9, CD63 and CD81 are commonly measured in extracellular-vesicle studies, but one positive band or certificate cannot prove that a mixture contains only exosomes, establish cellular origin or demonstrate clinical function. Multiple context-appropriate methods are needed.

This translation has no recorded clinical or medical-language review.

Direct answer

Tetraspanins are useful markers but are not specific to every EV subtype or source.
Positive markers should be paired with controls for non-vesicular and intracellular residues.
Identity characterization is separate from dose, sterility, potency and human benefit.

What does a marker show?

An antibody assay may show that a protein compatible with CD9, CD63 or CD81 is present. Abundance varies with cell source, culture conditions, separation and assay. No single tetraspanin is present on every vesicle or proves an endosomal origin. MISEV therefore favors the broader term extracellular vesicle unless a specific subcellular origin has been demonstrated.

Why multiple characterization methods matter

Different membrane-associated protein categories, cytosolic components, electron or high-resolution imaging, particle size and concentration provide complementary information. Negative controls for intracellular structures such as endoplasmic reticulum and common contaminants such as albumin may also be examined. No single assay proves identity, purity and biological function together; method and underlying data should be available for the lot.

From a certificate to a patient claim

Listing three markers on a certificate does not show that a product is sterile, stable, correctly dosed or clinically useful for skin. Cell source, manufacturing, carrier, endotoxin, mycoplasma, storage and route require separate verification. 'CD63 positive' should not be presented as an authorization or general quality seal. Laboratory identity must not be converted into an outcome promise without relevant human evidence.

Scope of this article

This content is not diagnosis, prescribing, personal risk assessment or a treatment plan. Sources may be limited to a particular product, device, task, indication or study group.

Sources and evidence limits

These links are editorial starting points used to examine the article's boundaries.

Microneedling for Facial Rejuvenation: A Systematic Review
Foppiani JA et al. · 2025
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Evaluating the Effectiveness and Safety of Radiofrequency for Face and Neck Rejuvenation: A Systematic Review
Austin GK, Struble SL, Quatela VC · 2022
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Energy-Based Devices for the Treatment of Facial Skin Conditions in Skin of Color
Sanyal RD, Fabi SG · 2024
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling – FDA Safety Communication
U.S. Food and Drug Administration (FDA) · 2025
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
A Systematic Review and Meta-Analysis of Efficacy, Safety, and Satisfaction Rates of Laser Combination Treatments vs Laser Monotherapy in Skin Rejuvenation Resurfacing
Pour Mohammad A et al. · 2023
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Outcomes and Adverse Effects of Ablative vs Nonablative Lasers for Skin Resurfacing: A Systematic Review of 1093 Patients
Mirza HN, Mirza FN, Khatri KA · 2021
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Medical Lasers
U.S. Food and Drug Administration (FDA) · 2023
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Minimal Information for Studies of Extracellular Vesicles (MISEV2023): From Basic to Advanced Approaches
International Society for Extracellular Vesicles consensus authors · 2024
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Framework for Rapid Comparison of Extracellular Vesicle Isolation Methods
Research authors; Journal of Extracellular Vesicles · 2022
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Public Safety Alert Due to Marketing of Unapproved Stem Cell and Exosome Products
U.S. Food and Drug Administration (FDA) · 2019
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review